NO20014535L - Inhibitorer av IMPDH-enzym - Google Patents
Inhibitorer av IMPDH-enzymInfo
- Publication number
- NO20014535L NO20014535L NO20014535A NO20014535A NO20014535L NO 20014535 L NO20014535 L NO 20014535L NO 20014535 A NO20014535 A NO 20014535A NO 20014535 A NO20014535 A NO 20014535A NO 20014535 L NO20014535 L NO 20014535L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- impdh enzyme
- impdh
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12550799P | 1999-03-19 | 1999-03-19 | |
US17488200P | 2000-01-07 | 2000-01-07 | |
PCT/US2000/007129 WO2000056331A1 (en) | 1999-03-19 | 2000-03-17 | Inhibitors of impdh enzyme |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20014535D0 NO20014535D0 (no) | 2001-09-18 |
NO20014535L true NO20014535L (no) | 2001-11-19 |
NO321932B1 NO321932B1 (no) | 2006-07-24 |
Family
ID=26823644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014535A NO321932B1 (no) | 1999-03-19 | 2001-09-18 | IMPDH-hemmende forbindelser og sammensetninger inneholdende disse samt deres anvendelse. |
Country Status (24)
Country | Link |
---|---|
US (4) | US6498178B2 (no) |
EP (2) | EP1178797B1 (no) |
JP (3) | JP4184610B2 (no) |
KR (1) | KR100652535B1 (no) |
CN (1) | CN1196687C (no) |
AP (1) | AP1498A (no) |
AR (1) | AR029341A1 (no) |
AU (1) | AU769383B2 (no) |
BG (1) | BG65563B1 (no) |
BR (1) | BR0009167A (no) |
CA (1) | CA2367017C (no) |
CZ (1) | CZ301802B6 (no) |
EA (1) | EA004141B1 (no) |
EE (1) | EE200100492A (no) |
ES (1) | ES2405316T3 (no) |
HU (1) | HUP0201214A3 (no) |
IL (2) | IL145475A0 (no) |
NO (1) | NO321932B1 (no) |
NZ (1) | NZ514540A (no) |
OA (1) | OA11848A (no) |
PL (1) | PL211562B1 (no) |
SK (1) | SK13332001A3 (no) |
TR (1) | TR200103428T2 (no) |
WO (1) | WO2000056331A1 (no) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
US6420403B1 (en) | 1998-10-29 | 2002-07-16 | Edwin J. Iwanowicz | Inhibitors of IMPDH enzyme |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
NZ514540A (en) * | 1999-03-19 | 2003-11-28 | Vertex Pharma | Phenyl derivative useful as inhibitors of IMPDH enzyme |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
ATE345130T1 (de) * | 2001-12-03 | 2006-12-15 | Bayer Pharmaceuticals Corp | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen |
CN1318404C (zh) | 2002-02-11 | 2007-05-30 | 拜耳制药公司 | 作为激酶抑制剂的芳基脲类化合物 |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
CA2510006C (en) * | 2002-12-06 | 2012-02-07 | Vertex Pharmaceuticals Incorporated | Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents |
DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
US20050090450A1 (en) | 2003-04-11 | 2005-04-28 | Farmer Luc J. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
BRPI0412761A (pt) | 2003-07-18 | 2006-09-26 | Vertex Pharma | inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc |
PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
DE10336185A1 (de) * | 2003-08-07 | 2005-02-24 | Bayer Chemicals Ag | Enantiomerenangereicherte 1-Phenylethylamine |
US7156615B2 (en) * | 2003-08-21 | 2007-01-02 | Siemens Vdo Automotive Inc. | Fan shroud structure for reducing resonance, improving stiffness and manufacturability |
AR045596A1 (es) | 2003-09-05 | 2005-11-02 | Vertex Pharma | Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc |
TW200518669A (en) * | 2003-09-12 | 2005-06-16 | Vertex Pharma | Animal model for protease activity and liver damage |
AR045769A1 (es) | 2003-09-18 | 2005-11-09 | Vertex Pharma | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) |
WO2005037860A2 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
AU2004285019B9 (en) | 2003-10-27 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
EP1711515A2 (en) | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2560818A1 (en) * | 2004-03-23 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester |
MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
BRPI0511290A (pt) * | 2004-05-21 | 2007-12-18 | Uab Research Foundation | composições e métodos referentes aos inibidores da sìntese da pirimidina |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
US20080267915A1 (en) * | 2004-10-01 | 2008-10-30 | Vertex Pharmaceuticals | Hcv Ns3-Ns4a Protease Inhibition |
MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
JP2008543742A (ja) * | 2005-05-09 | 2008-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ビアリール尿素およびそのアナログの調製プロセス |
WO2006127909A2 (en) * | 2005-05-26 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate |
BRPI0614638A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para a preparação dos mesmos, combinação e composição farmacêutica |
KR101381387B1 (ko) | 2005-07-29 | 2014-04-11 | 메디비르 아베 | C형 간염 바이러스의 마크로사이클릭 억제제 |
US8183277B2 (en) | 2005-07-29 | 2012-05-22 | Tibotec Pharmaceuticals Ltd. | Macrocylic inhibitors of hepatitis C virus |
JP5230417B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | C型肝炎ウイルスの大員環インヒビター |
TWI383980B (zh) * | 2005-07-29 | 2013-02-01 | Tibotec Pharm Ltd | C型肝炎病毒之大環抑制劑 |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
PL1919899T3 (pl) | 2005-07-29 | 2011-06-30 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
US20070105781A1 (en) * | 2005-08-02 | 2007-05-10 | Steve Lyons | Inhibitors of serine proteases |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
KR20140098867A (ko) | 2005-11-11 | 2014-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | C형 간염 바이러스 변이체 |
US8791110B2 (en) | 2006-02-01 | 2014-07-29 | Siga Technologies, Inc. | Anti-arenaviral compounds |
CA2640687A1 (en) | 2006-02-01 | 2007-10-25 | Siga Technologies, Inc. | Anti-arenaviral compounds |
JP5436864B2 (ja) | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vx−950を含む共結晶体およびそれを含む医薬組成物 |
MX2008011868A (es) | 2006-03-16 | 2008-12-15 | Vertex Pharma | Inhibidores deuterados de la proteasa de la hepatitis c. |
US7825152B2 (en) | 2006-04-11 | 2010-11-02 | Novartis Ag | Organic compounds and their uses |
FR2901273B1 (fr) | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
WO2008040778A2 (en) | 2006-10-04 | 2008-04-10 | Tibotec Pharmaceuticals Ltd. | Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c |
US8980940B2 (en) | 2006-11-10 | 2015-03-17 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
ES2470568T3 (es) | 2006-11-17 | 2014-06-24 | Janssen R&D Ireland | Inhibidores macroc�clicos del virus de la hepatitis C |
WO2008095999A1 (en) | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Pyrimidine substituted macrocyclic hcv inhibitors |
EA200970806A1 (ru) | 2007-02-27 | 2010-08-30 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
CN101903392A (zh) | 2007-02-27 | 2010-12-01 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶的抑制剂 |
ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
JP5443360B2 (ja) * | 2007-08-30 | 2014-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶体およびそれを含む医薬組成物 |
US20090082452A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lumiracoxib |
US8524716B2 (en) | 2007-12-24 | 2013-09-03 | Janssen R&D Ireland | Macrocyclic indoles as hepatitis C virus inhibitors |
US9066951B2 (en) * | 2008-05-29 | 2015-06-30 | Wisconsin Alumni Research Foundation | Drugs to treat HPV infection |
TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
AU2009281138B2 (en) | 2008-08-14 | 2014-03-27 | Tibotec Pharmaceuticals | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors |
PT2373172E (pt) | 2008-12-03 | 2013-10-21 | Presidio Pharmaceuticals Inc | Inibidores de ns5a de hcv |
SG171891A1 (en) | 2008-12-03 | 2011-07-28 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
EP2396028A2 (en) | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
WO2010111534A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis c |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
EP2528605A1 (en) | 2010-01-29 | 2012-12-05 | Vertex Pharmaceuticals Incorporated | Therapies for treating hepatitis c virus infection |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
WO2011161232A1 (en) | 2010-06-24 | 2011-12-29 | Tibotec Pharmaceuticals | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID |
EP2593105A1 (en) | 2010-07-14 | 2013-05-22 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition comprising vx-950 |
WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
WO2012058125A1 (en) | 2010-10-26 | 2012-05-03 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
WO2012116370A1 (en) | 2011-02-25 | 2012-08-30 | Medtronic, Inc. | Methods and systems using pharmacokinetic and pharmacodynamic profiles in interferon-alpha therapeutic regimens |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
RU2014102102A (ru) | 2011-06-23 | 2015-07-27 | Дигна Байотек, С.Л. | КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С |
US20120328565A1 (en) | 2011-06-24 | 2012-12-27 | Brinkman John A | Antiviral compounds |
WO2013053657A1 (en) | 2011-10-10 | 2013-04-18 | F. Hoffmann-La Roche Ag | Antiviral compounds |
US9133170B2 (en) | 2011-12-16 | 2015-09-15 | Hoffmann-La Roche Inc. | Inhibitors of HCV NS5A |
JP6118336B2 (ja) | 2011-12-20 | 2017-04-19 | リボサイエンス・エルエルシー | Hcvのrna複製の阻害剤としての4’−アジド、3’−フルオロ置換されたヌクレオシド誘導体 |
EP2794629B1 (en) | 2011-12-20 | 2017-05-24 | Riboscience LLC | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
RU2621734C1 (ru) | 2011-12-28 | 2017-06-07 | Янссен Сайенсиз Айрлэнд Юси | Гетеробициклические производные в качестве ингибиторов hcv |
WO2013116339A1 (en) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
RU2014137052A (ru) | 2012-02-24 | 2016-04-10 | Ф.Хоффманн-Ля Рош Аг | Противовирусные соединения |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
WO2014114573A1 (en) | 2013-01-23 | 2014-07-31 | F. Hoffmann-La Roche Ag | Antiviral triazole derivatives |
MX2015011193A (es) | 2013-03-05 | 2015-11-13 | Hoffmann La Roche | Compuestos antivirales. |
KR102241198B1 (ko) | 2013-05-16 | 2021-04-15 | 리보사이언스 엘엘씨 | 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체 |
WO2014193663A1 (en) | 2013-05-16 | 2014-12-04 | Riboscience Llc | 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
MX2016005283A (es) | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
WO2017223178A1 (en) * | 2016-06-21 | 2017-12-28 | Trek Therapeutics, Pbc | Treating viral infections with impdh inhibitors |
JP7299897B2 (ja) | 2017-09-21 | 2023-06-28 | リボサイエンス リミティド ライアビリティ カンパニー | Hcvのrna複製阻害剤としての4’-フルオロ-2’-メチル置換ヌクレオシド誘導体 |
CA3094324A1 (en) | 2018-03-26 | 2019-10-03 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
DK180212B1 (en) * | 2018-05-07 | 2020-08-19 | Apple Inc | USER INTERFACE FOR CREATING AVATAR |
CN109970675A (zh) * | 2018-05-28 | 2019-07-05 | 中国医学科学院医药生物技术研究所 | 一组硫脲化合物及其制备方法和应用 |
CA3100957A1 (en) | 2018-06-19 | 2019-12-26 | Novartis Ag | N-substituted tetrahydrothienopyridine derivatives and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283257A (en) | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
DE4228000A1 (de) | 1992-08-24 | 1994-03-03 | Bayer Ag | 3-Aryl-triazin-2,4-dione |
WO1994012184A1 (en) | 1992-11-24 | 1994-06-09 | Syntex (U.S.A.) Inc. | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
US5444072A (en) | 1994-02-18 | 1995-08-22 | Syntex (U.S.A.) Inc. | 6-substituted mycophenolic acid and derivatives |
US5380879A (en) | 1994-02-18 | 1995-01-10 | Syntex (U.S.A.) Inc. | Derivatives of mycophenolic acid |
US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
CN1515248A (zh) | 1996-04-23 | 2004-07-28 | ��̩��˹ҩ��ɷ�����˾ | 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物 |
US6128582A (en) * | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
US5932600A (en) * | 1997-03-14 | 1999-08-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
WO1998040381A1 (en) * | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
NZ514540A (en) | 1999-03-19 | 2003-11-28 | Vertex Pharma | Phenyl derivative useful as inhibitors of IMPDH enzyme |
US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
US6395763B1 (en) * | 1999-06-25 | 2002-05-28 | Vertex Pharmaceuticals Incorporated | Prodrugs of carbamate inhibitors of IMPDH |
US6471980B2 (en) * | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US7083642B2 (en) * | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US6939375B2 (en) * | 2000-12-22 | 2005-09-06 | Avantac Vascular Corporation | Apparatus and methods for controlled substance delivery from implanted prostheses |
US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
-
2000
- 2000-03-17 NZ NZ514540A patent/NZ514540A/en not_active IP Right Cessation
- 2000-03-17 EP EP00916479A patent/EP1178797B1/en not_active Expired - Lifetime
- 2000-03-17 CZ CZ20013349A patent/CZ301802B6/cs not_active IP Right Cessation
- 2000-03-17 AR ARP000101205A patent/AR029341A1/es active IP Right Grant
- 2000-03-17 EP EP08006361A patent/EP1964561A1/en not_active Withdrawn
- 2000-03-17 OA OA1200100235A patent/OA11848A/en unknown
- 2000-03-17 WO PCT/US2000/007129 patent/WO2000056331A1/en active IP Right Grant
- 2000-03-17 KR KR1020017011959A patent/KR100652535B1/ko not_active IP Right Cessation
- 2000-03-17 CA CA002367017A patent/CA2367017C/en not_active Expired - Fee Related
- 2000-03-17 EE EEP200100492A patent/EE200100492A/xx unknown
- 2000-03-17 CN CNB008064571A patent/CN1196687C/zh not_active Expired - Fee Related
- 2000-03-17 BR BR0009167-7A patent/BR0009167A/pt not_active IP Right Cessation
- 2000-03-17 JP JP2000606236A patent/JP4184610B2/ja not_active Expired - Fee Related
- 2000-03-17 TR TR2001/03428T patent/TR200103428T2/xx unknown
- 2000-03-17 SK SK1333-2001A patent/SK13332001A3/sk unknown
- 2000-03-17 PL PL350911A patent/PL211562B1/pl not_active IP Right Cessation
- 2000-03-17 EA EA200100992A patent/EA004141B1/ru not_active IP Right Cessation
- 2000-03-17 ES ES00916479T patent/ES2405316T3/es not_active Expired - Lifetime
- 2000-03-17 AU AU37577/00A patent/AU769383B2/en not_active Ceased
- 2000-03-17 IL IL14547500A patent/IL145475A0/xx not_active IP Right Cessation
- 2000-03-17 AP APAP/P/2001/002298A patent/AP1498A/en active
- 2000-03-17 HU HU0201214A patent/HUP0201214A3/hu unknown
-
2001
- 2001-09-16 IL IL145475A patent/IL145475A/en unknown
- 2001-09-18 NO NO20014535A patent/NO321932B1/no not_active IP Right Cessation
- 2001-09-19 US US09/955,626 patent/US6498178B2/en not_active Expired - Lifetime
- 2001-10-16 BG BG106020A patent/BG65563B1/bg unknown
-
2002
- 2002-11-04 US US10/287,405 patent/US7087642B2/en not_active Expired - Lifetime
-
2004
- 2004-11-24 US US10/997,810 patent/US7432290B2/en not_active Expired - Fee Related
-
2007
- 2007-12-07 JP JP2007316708A patent/JP4227182B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-07 JP JP2008098934A patent/JP2008255116A/ja active Pending
- 2008-08-07 US US12/221,921 patent/US8268873B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20014535L (no) | Inhibitorer av IMPDH-enzym | |
NO984917L (no) | Ureaderivater som inhibitorer av IMPDH-enzym | |
EP1127054A4 (en) | INHIBITORS OF IMPDH ENZYME | |
NO20004219D0 (no) | Inhibitorer av fosfolipaseenzymer | |
NO20004220D0 (no) | Inhibitorer av fosfolipaseenzymer | |
DE60020100D1 (de) | Dimerverbindungen und als inhibitoren der neuramidinase | |
AU3665199A (en) | Inhibitors of impdh enzyme | |
AU5553801A (en) | Heterocycles that are inhibitors of impdh enzyme | |
NO20004550D0 (no) | Enzyminhibitorer | |
NO20005673L (no) | Heterocykliske inhibitorer av P38 | |
NO20015601D0 (no) | Enzym-instantformuleringer av enzymer for dyrefôr | |
DE69905582T2 (de) | Heterocyclische verbindungen als rotamase-enzymen inhibitoren | |
NO20016252D0 (no) | Fremgangsmåte for nedregulering av GDF-8 aktivitet | |
NO20016034L (no) | Inhibitorer av aspartylprotease | |
MA26818A1 (fr) | Formulations contenant des inhibiteurs de lipase | |
NO993717D0 (no) | Anvendelse av gastrointestinale lipase-inhibitorer | |
FI19992855A (fi) | Valaisuolosuhteiden mittaus | |
NO20005293D0 (no) | Visse tiolininhibitorer av endotelinomdannende enzym | |
FR2816843B1 (fr) | Inhibiteurs de l'enzyme 5 alpha-reductase | |
DE60038350D1 (de) | Angiotensin-Converting-Enzyme-Hemmer | |
DE60024101D1 (de) | Enzyminhibitoren | |
PT1178984E (pt) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano | |
DE60033943D1 (de) | Schwefelfreie enzyme | |
NO20013669D0 (no) | Reverse hydroksamatinhibitorer av matriks metalloproteinaser | |
NO20014845D0 (no) | Anvendelse av arylalkanoylpyridaziner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |